Therapeutic role of lactoferrin against doxorubicin-induced cardiotoxicity.
Therapeutic role of lactoferrin against doxorubicin-induced cardiotoxicity in Wistar rats.
AI Summary
Key Findings
Abstract
INTRODUCTION AND OBJECTIVES: Doxorubicin-associated cardiotoxicity is an alarming concern as it limits the use of anticancer drugs in a clinical setting. The objective of this study was to test the therapeutic role of lactoferrin in preventing doxorubicin-induced cardiotoxicity and thus address this severe side effect of chemotherapy. METHODS: Wistar rats received vehicle or DOX (2.5 mg/kg, i.p.) three times a week for two weeks and lactoferrin (50 mg/kg, i.p.) for 15 days (i.e., from day 1 to day 15 along with DOX). Changes in body weight, heart weight, and cardiotoxicity markers (blood pressure, LDH, CK-MB, and cardiac troponin I) were evaluated. Furthermore, all the animals were evaluated for the modulation of inflammatory markers (BNP, IL-6, CRP, and TNF-α), histopathological changes in heart tissue, and oxidant and antioxidant status. RESULTS: Doxorubicin significantly (p
Affiliation
Vinay Kumar
External References
- PubMed ID:
- 42097359
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.